Pediatric Wilms' Tumor (TARGET, 2018)

Summary

Pediatric Wilms' Tumor (TARGET, 2018) is a study catalogued by cBioPortal DataHub under the cancer-type code wt. EvidenceHelix groups it with kidney and bladder studies.

Study description

Whole-exome sequencing of 657 Wilms' tumor samples. Comprehensive profiling of 657 Wilms' Tumor samples. TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see Using TARGET Data (https://ocg.cancer.gov/programs/target/using-target-data) section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the TARGET Publication Guidelines (https://ocg.cancer.gov/programs/target/target-publication-guidelines).

Text as published in the source's study metadata.

Citation & PubMed

The source lists no citation or PubMed id for this study.

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

wt_target_2018_pub

Short name

WT (TARGET, 2018)

Source cancer-type code

wt

Reference genome

not given

Source access groups

NCI-TARGET;PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

The source lists no citation or PubMed id for this study.

Related studies

• Bladder Cancer (Columbia University/MSK, Cell 2018)

  Targeted sequencing of 130 bladder cancer tumors, organoids and xenografts and their matched normals via MSK-IMPACT.

  Kidney and bladderMSK studiesSource code bladderPubMed 1

• Bladder Cancer (MSK, Cell Reports 2022)

  Targeted sequencing of 1659 Bladder Cancer tumor/normal samples via MSK-IMPACT.

  Kidney and bladderMSK studiesSource code bladderPubMed 1

• Bladder Cancer (MSK, Clin Cancer Res 2023)

  Targeted sequencing of 526 bladder tumors and their matched normals via MSK-IMPACT.

  Kidney and bladderMSK studiesSource code bladderPubMed 1

• Bladder Cancer (MSK, Eur Urol 2014)

  Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. Targeted sequencing of 109 tumor samples (MSKCC, European Urology 2014).

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK, J Clin Onco 2013)

  Comprehensive profiling of 97 high-grade bladder tumors, including targeted sequencing of 15 cancer genes

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK, Nat Genet 2016)

  Whole exome and targeted sequencing of 34 plasmacytoid-variant (signet ring cell) tumors of the bladder

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK/TCGA, 2020)

  Whole-exome or targeted sequencing of 476 muscle-invasive bladder tumor/normal pairs via TCGA or MSK-IMPACT sequencing.

  Kidney and bladderTCGA (other releases)Source code blcaPubMed 1

• Bladder Cancer (TCGA, Cell 2017)

  Whole-exome sequencing of 412 muscle-invasive bladder tumors and matched normal samples.

  Kidney and bladderTCGA (other releases)Source code blcaPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.